Star Scientific Announces Acceleration of Plans to Submit IND to FDA for Pharmaceutical Version of Anatabine Compound

By: Benzinga
Star Scientific (NASDAQ: STSI ) today announced that the Company has filed its preliminary proxy statement on Form 14A with the Securities and Exchange Commission in preparation for its December 27 annual shareholder meeting. The proxy statement outlines the Company's plan to accelerate the submission of an Investigational New
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.